Scholarlink

Introduction and Importance <p>Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), is increasingly used for glycemic control, weight loss, and cardiovascular risk reduction. While GLP-1 RAs are commonly associated with acute pancreatitis, emerging reports suggest a possible association with pancreatic cystic lesions, even in patients without typical risks factors such as alcohol, gallstones, or hereditary syndromes.</p> Case Presentation <p>We present two cases of middle-age female patients without prior compline or pancreatic disease who developed large distal pancreatic mucinous cystic neoplasms following GLP-1 Ras use. Both underwent imaging and aspiration, which revealed elevated carcinoembryonic antigen (CEA) levels. Surgical management consisted of distal pancreatectomy and splenectomy. Pathology confirmed MCN with no malignancy. Both patients had uneventful recovery.</p> Discussion <p>These two cases suggest a possible association between GLP-1 receptor agonists, and the development of pancreatic mucinous cystic neoplasms (MCNs) in patients without prior pancreatic disease or conventional risk factors. While causality cannot be established, the temporal relationship, absence of alternative etiologies, and supportive literature suggest a possible drug-related effect. Preclinical studies have implicated GLP-1 RAs in pancreatic ductal hyperplasia and cyst formation, and recent clinical reports reinforce these findings. As semaglutide use expands, clinicians should be vigilant for structural pancreatic changes, and further studies are warranted to elucidate underlying mechanisms and clinical implications.</p> Conclusion <p>These cases raise concern regarding a potential association between semaglutide therapy and mucinous cystic neoplasms. Increased vigilance and further observational studies are warranted to evaluate this potential adverse effect.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pancreatic Mucinous Cystic Neoplasms Following GLP-1 Receptor Agonists Use: A Report of Two Cases with Literature Review

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月29日

查看全文
  • Nourah Mohammed Alsaleh,
  • Renad Abo Alshamat,
  • Wejdan Almrzouqi,
  • Mohammed Alhebshi,
  • Turky Aljuhani,
  • Rahf Almahdi,
  • Majed Almaghrabi,
  • Almotasembillah Rammal,
  • Amro Ageel,
  • Mohammed Ahmad Alzahrani

摘要

Introduction and Importance

Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), is increasingly used for glycemic control, weight loss, and cardiovascular risk reduction. While GLP-1 RAs are commonly associated with acute pancreatitis, emerging reports suggest a possible association with pancreatic cystic lesions, even in patients without typical risks factors such as alcohol, gallstones, or hereditary syndromes.

Case Presentation

We present two cases of middle-age female patients without prior compline or pancreatic disease who developed large distal pancreatic mucinous cystic neoplasms following GLP-1 Ras use. Both underwent imaging and aspiration, which revealed elevated carcinoembryonic antigen (CEA) levels. Surgical management consisted of distal pancreatectomy and splenectomy. Pathology confirmed MCN with no malignancy. Both patients had uneventful recovery.

Discussion

These two cases suggest a possible association between GLP-1 receptor agonists, and the development of pancreatic mucinous cystic neoplasms (MCNs) in patients without prior pancreatic disease or conventional risk factors. While causality cannot be established, the temporal relationship, absence of alternative etiologies, and supportive literature suggest a possible drug-related effect. Preclinical studies have implicated GLP-1 RAs in pancreatic ductal hyperplasia and cyst formation, and recent clinical reports reinforce these findings. As semaglutide use expands, clinicians should be vigilant for structural pancreatic changes, and further studies are warranted to elucidate underlying mechanisms and clinical implications.

Conclusion

These cases raise concern regarding a potential association between semaglutide therapy and mucinous cystic neoplasms. Increased vigilance and further observational studies are warranted to evaluate this potential adverse effect.